Solicitation for Public Comments on Questions From the National Clinical Care Commission, 2429-2430 [2020-00505]

Download as PDF Federal Register / Vol. 85, No. 10 / Wednesday, January 15, 2020 / Notices 2429 PICOTS (POPULATIONS, INTERVENTIONS, COMPARATORS, OUTCOMES, TIMING, SETTINGS)—Continued PICOTS elements Inclusion criteria Exclusion criteria Timing ................. At the following intervals: <1 Day; 1 day to <1 week; 1 week to <2 weeks; 2 weeks to 4 weeks. None. Settings ............... ER, physician’s office, hospital ................................................ None. Study design ....... • Original studies: Æ RCTs. Æ Comparative observational studies. • Any sample size. • Relevant systematic reviews, or meta-analyses (used for identifying additional studies) In vitro studies, non-original data (e.g., narrative reviews, editorials, letters, or erratum), single-arm observational studies, case series, qualitative studies, cost-benefit analysis, cross-sectional (i.e., non-longitudinal) studies, beforeafter studies, survey. Publications ......... Studies published in English only ............................................ Foreign language studies. Abbreviations: RCT = randomized controlled trial. Dated: January 9, 2020. Virginia L. Mackay-Smith, Associate Director, Office of the Director, AHRQ. [FR Doc. 2020–00488 Filed 1–14–20; 8:45 am] BILLING CODE 4160–90–P DEPARTMENT OF HEALTH AND HUMAN SERVICES [Docket No. HHS–OS–2019–0015] Solicitation for Public Comments on Questions From the National Clinical Care Commission Office of Disease Prevention and Health Promotion, Office of the Assistant Secretary for Health, Office of the Secretary, Department of Health and Human Services. ACTION: Request for public comment. AGENCY: The National Clinical Care Commission (the Commission) solicits public comments on a set of questions concerning the context, policies, effectiveness, promising practices, and limitations and gaps related to prevention and treatment of diabetes and its complications. The Commission is charged to evaluate and make recommendations to the Secretary of Health and Human Services (HHS) and Congress regarding improvements to the coordination and leveraging of federal programs related to awareness and clinical care for diabetes and its complications. The set of questions is available in the SUPPLEMENTARY INFORMATION section, below. DATES: Electronic or written/paper comments will be accepted through midnight Eastern Standard Time (EST) February 3, 2020. ADDRESSES: Public comments can be submitted in the following ways: • Electronic submissions can be filed on the online docket at http:// www.regulations.gov by following the jbell on DSKJLSW7X2PROD with NOTICES SUMMARY: VerDate Sep<11>2014 17:18 Jan 14, 2020 Jkt 250001 ‘‘Instructions for Public Comments’’ section, below. Evidence and information supporting your comments can be submitted as attachments. Comments submitted electronically, including supporting attachments, will be posted to the docket unchanged. Please provide your contact information or organization name on the web-based form for potential follow up by the Commission. • If you prefer to comment on paper, mail your comments to the following address: Public Commentary, National Clinical Care Commission, 1101 Wootton Parkway, Suite 420, Rockville, MD 20852. For mailed submissions, the Office of Disease Prevention and Health Promotion will post your comments, as well as any attachments, to http:// www.regulations.gov. Instructions for Public Comments: All electronic submissions must be submitted in the Docket ID HHS–OS– 2019–0015 for ‘‘Solicitation for Public Comments on Questions from the National Clinical Care Commission.’’ For access to the docket to provide and/ or read all comments received, go to https://www.regulations.gov and insert the docket ID HHS–OS–2019–0015 into the search box and follow the prompts. Comments are encouraged from the public and will be accepted through February 3, 2020. The https:// www.regulations.gov electronic filing system will accept electronic comments until midnight Eastern Standard Time at the end of February 3, 2020. Comments received by mail/courier will be considered if they are postmarked or the delivery service acceptance receipt date is on or before that date. Written comments via mail will be uploaded into https://www.regulations.gov and are under the same limitations as for those directly submitted electronically into https://www.regulations.gov: 5,000character limit for text box, and maximum number (10) of attached files PO 00000 Frm 00047 Fmt 4703 Sfmt 4703 and maximum size (10 MB) of each attached file. FOR FURTHER INFORMATION CONTACT: Linda Harris, Designated Federal Officer, National Clinical Care Commission, U.S. Department of Health and Human Services, Office of the Assistant Secretary for Health, Office of Disease Prevention and Health Promotion, 1101 Wootton Parkway, Suite 420, Rockville, MD 20852. Email: linda.harris@hhs.gov. SUPPLEMENTARY INFORMATION: The National Clinical Care Commission Act (Pub. L. 115–80) requires the HHS Secretary to establish the National Clinical Care Commission. The Commission consists of representatives of specific federal agencies and nonfederal individuals and entities who represent diverse disciplines and views. The Commission will evaluate and make recommendations to the HHS Secretary and Congress regarding improvements to the coordination and leveraging of federal programs related to awareness and clinical care for diabetes and its complications. The Commission invites members of the public to comment on any issues or concerns they believe are relevant or appropriate to the Commission’s evaluation of federal programs. Specifically, the Commission requests public comment on the following questions: 1. Context: What social, economic, and/or environmental factors have the greatest impact on health care in general—and also on prevention (Type 2) and/or management of diabetes (both Type 1 and Type 2)? What can be done by the federal government to address those social/economic/environmental factors? 2. Policies: What policies should the federal government implement to improve diabetes prevention and/or management? What is the evidence to support those? E:\FR\FM\15JAN1.SGM 15JAN1 2430 Federal Register / Vol. 85, No. 10 / Wednesday, January 15, 2020 / Notices 3. Effectiveness: What specific recommendations do you have for federal agencies to be more effective and/or to collaborate better to prevent and/or help manage diabetes? What is the basis for your specific recommendations? 4. Promising Practices: What are the best and/or most promising practices to prevent diabetes and/or to improve diabetes outcomes? What is the evidence to support them? 5. Limitations and gaps: What are the greatest limitations or gaps in federal programs to prevent diabetes and/or to improve diabetes outcomes? What could the Federal government do to close the gaps? Are there specific research needs? Are there specific research needs or programs that would benefit from new or increased collaboration across federal agencies? Don Wright, Deputy Assistant Secretary for Health, Disease Prevention and Health Promotion. [FR Doc. 2020–00505 Filed 1–14–20; 8:45 am] BILLING CODE 4150–32–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute on Deafness and Other Communication Disorders; Notice of Closed Meetings jbell on DSKJLSW7X2PROD with NOTICES Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute on Deafness and Other Communication Disorders Special Emphasis Panel; NIDCD Voice, Speech, Language Application Review. Date: February 10, 2020. Time: 11:00 a.m. to 2:30 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, NIDCD, Neuroscience Center, 6001 Executive Blvd., Ste. 8300, Bethesda, MD 20892 (Telephone Conference Call). Contact Person: Shiguang Yang, DVM, Ph.D., Scientific Review Officer, Division of VerDate Sep<11>2014 17:18 Jan 14, 2020 Jkt 250001 Extramural Activities, NIDCD, NIH, 6001 Executive Blvd., Room 8349, Bethesda, MD 20892, (301) 496–8683, yangshi@ nidcd.nih.gov. Name of Committee: National Institute on Deafness and Other Communication Disorders Special Emphasis Panel; Hearing and Balance Application Review. Date: February 11, 2020. Time: 8:00 a.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: Canopy by Hilton, 940 Rose Avenue, North Bethesda, MD 20852. Contact Person: Eliane Lazar-Wesley, Ph.D., Scientific Review Officer, Scientific Review Branch, Division of Extramural Activities, National Institutes of Health, NIDCD, 6001 Executive Boulevard, Room 8339, MSC 9670, Bethesda, MD 20892–8401, (301) 496–8683, el6r@nih.gov. Name of Committee: National Institute on Deafness and Other Communication Disorders Special Emphasis Panel; Chemical Senses Fellowship Review. Date: February 19, 2020. Time: 1:00 p.m. to 4:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, NIDCD, Neuroscience Center, 6001 Executive Blvd., Bethesda, MD 20892 (Telephone Conference Call). Contact Person: Sheo Singh, Ph.D., Scientific Review Officer, Scientific Review Branch, Division of Extramural Activities, National Institutes of Health, NIDCD, 6001 Executive Blvd., Room 8351, Bethesda, MD 20892, (301) 496–8683, singhs@ nidcd.nih.gov. Name of Committee: National Institute on Deafness and Other Communication Disorders Special Emphasis Panel; NIDCD Clinical Trial Review. Date: February 21, 2020. Time: 2:00 p.m. to 3:30 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, NIDCD, Neuroscience Building, 6001 Executive Blvd., Ste. 8300, Bethesda, MD 20892 (Telephone Conference Call). Contact Person: Katherine Shim, Ph.D., Scientific Review Officer, Division of Extramural Activities, National Institutes of Health, NIDCD, 6001 Executive Blvd., Room 8351, Bethesda, MD 20892, (301) 496–8683, katherine.shim@nih.gov. Name of Committee: National Institute on Deafness and Other Communication Disorders Special Emphasis Panel; NIDCD Clinical Research Center Review. Date: March 10, 2020. Time: 12:00 p.m. to 4:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, NIDCD, Neuroscience Center, 6001 Executive Blvd., Ste. 8300, Bethesda, MD 20892 (Telephone Conference Call). Contact Person: Katherine Shim, Ph.D., Scientific Review Officer, Division of Extramural Activities, National Institutes of Health, NIDCD, 6001 Executive Blvd., Room 8351, Bethesda, MD 20892, (301) 496–8683, katherine.shim@nih.gov. PO 00000 Frm 00048 Fmt 4703 Sfmt 4703 Name of Committee: National Institute on Deafness and Other Communication Disorders Special Emphasis Panel; NIDCD (U01) Cooperative Agreement for Clinical Trials in Communication Disorders. Date: March 12, 2020. Time: 2:00 p.m. to 4:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, NIDCD, Neuroscience Center, 6001 Executive Blvd., Bethesda, MD 20892 (Telephone Conference Call). Contact Person: Eliane Lazar-Wesley, Ph.D., Scientific Review Officer, Scientific Review Branch, Division of Extramural Activities, National Institutes of Health, NIDCD, 6001 Executive Boulevard, Room 8339, MSC 9670, Bethesda, MD 20892–8401, (301) 496–8683, el6r@nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.173, Biological Research Related to Deafness and Communicative Disorders, National Institutes of Health, HHS) Dated: January 9, 2020. Miguelina Perez, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2020–00475 Filed 1–14–20; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Center for Scientific Review; Notice of Closed Meetings Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: Biological Chemistry and Macromolecular Biophysics Integrated Review Group; Biochemistry and Biophysics of Membranes Study Section. Date: February 4, 2020. Time: 8:00 a.m. to 8:00 p.m. Agenda: To review and evaluate grant applications. Place: Hyatt Regency Bethesda, One Bethesda Metro Center, 7400 Wisconsin Avenue, Bethesda, MD 20814. Contact Person: Nuria E Assa-Munt, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4164, E:\FR\FM\15JAN1.SGM 15JAN1

Agencies

[Federal Register Volume 85, Number 10 (Wednesday, January 15, 2020)]
[Notices]
[Pages 2429-2430]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-00505]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

[Docket No. HHS-OS-2019-0015]


Solicitation for Public Comments on Questions From the National 
Clinical Care Commission

AGENCY: Office of Disease Prevention and Health Promotion, Office of 
the Assistant Secretary for Health, Office of the Secretary, Department 
of Health and Human Services.

ACTION: Request for public comment.

-----------------------------------------------------------------------

SUMMARY: The National Clinical Care Commission (the Commission) 
solicits public comments on a set of questions concerning the context, 
policies, effectiveness, promising practices, and limitations and gaps 
related to prevention and treatment of diabetes and its complications. 
The Commission is charged to evaluate and make recommendations to the 
Secretary of Health and Human Services (HHS) and Congress regarding 
improvements to the coordination and leveraging of federal programs 
related to awareness and clinical care for diabetes and its 
complications. The set of questions is available in the SUPPLEMENTARY 
INFORMATION section, below.

DATES: Electronic or written/paper comments will be accepted through 
midnight Eastern Standard Time (EST) February 3, 2020.

ADDRESSES: Public comments can be submitted in the following ways:
     Electronic submissions can be filed on the online docket 
at http://www.regulations.gov by following the ``Instructions for 
Public Comments'' section, below. Evidence and information supporting 
your comments can be submitted as attachments. Comments submitted 
electronically, including supporting attachments, will be posted to the 
docket unchanged. Please provide your contact information or 
organization name on the web-based form for potential follow up by the 
Commission.
     If you prefer to comment on paper, mail your comments to 
the following address: Public Commentary, National Clinical Care 
Commission, 1101 Wootton Parkway, Suite 420, Rockville, MD 20852. For 
mailed submissions, the Office of Disease Prevention and Health 
Promotion will post your comments, as well as any attachments, to 
http://www.regulations.gov.
    Instructions for Public Comments: All electronic submissions must 
be submitted in the Docket ID HHS-OS-2019-0015 for ``Solicitation for 
Public Comments on Questions from the National Clinical Care 
Commission.'' For access to the docket to provide and/or read all 
comments received, go to https://www.regulations.gov and insert the 
docket ID HHS-OS-2019-0015 into the search box and follow the prompts.
    Comments are encouraged from the public and will be accepted 
through February 3, 2020. The https://www.regulations.gov electronic 
filing system will accept electronic comments until midnight Eastern 
Standard Time at the end of February 3, 2020. Comments received by 
mail/courier will be considered if they are postmarked or the delivery 
service acceptance receipt date is on or before that date. Written 
comments via mail will be uploaded into https://www.regulations.gov and 
are under the same limitations as for those directly submitted 
electronically into https://www.regulations.gov: 5,000-character limit 
for text box, and maximum number (10) of attached files and maximum 
size (10 MB) of each attached file.

FOR FURTHER INFORMATION CONTACT: Linda Harris, Designated Federal 
Officer, National Clinical Care Commission, U.S. Department of Health 
and Human Services, Office of the Assistant Secretary for Health, 
Office of Disease Prevention and Health Promotion, 1101 Wootton 
Parkway, Suite 420, Rockville, MD 20852. Email: [email protected].

SUPPLEMENTARY INFORMATION: The National Clinical Care Commission Act 
(Pub. L. 115-80) requires the HHS Secretary to establish the National 
Clinical Care Commission. The Commission consists of representatives of 
specific federal agencies and non-federal individuals and entities who 
represent diverse disciplines and views. The Commission will evaluate 
and make recommendations to the HHS Secretary and Congress regarding 
improvements to the coordination and leveraging of federal programs 
related to awareness and clinical care for diabetes and its 
complications.
    The Commission invites members of the public to comment on any 
issues or concerns they believe are relevant or appropriate to the 
Commission's evaluation of federal programs. Specifically, the 
Commission requests public comment on the following questions:
    1. Context: What social, economic, and/or environmental factors 
have the greatest impact on health care in general--and also on 
prevention (Type 2) and/or management of diabetes (both Type 1 and Type 
2)? What can be done by the federal government to address those social/
economic/environmental factors?
    2. Policies: What policies should the federal government implement 
to improve diabetes prevention and/or management? What is the evidence 
to support those?

[[Page 2430]]

    3. Effectiveness: What specific recommendations do you have for 
federal agencies to be more effective and/or to collaborate better to 
prevent and/or help manage diabetes? What is the basis for your 
specific recommendations?
    4. Promising Practices: What are the best and/or most promising 
practices to prevent diabetes and/or to improve diabetes outcomes? What 
is the evidence to support them?
    5. Limitations and gaps: What are the greatest limitations or gaps 
in federal programs to prevent diabetes and/or to improve diabetes 
outcomes? What could the Federal government do to close the gaps? Are 
there specific research needs? Are there specific research needs or 
programs that would benefit from new or increased collaboration across 
federal agencies?

Don Wright,
Deputy Assistant Secretary for Health, Disease Prevention and Health 
Promotion.
[FR Doc. 2020-00505 Filed 1-14-20; 8:45 am]
BILLING CODE 4150-32-P